Restoring trust in the pharmaceutical sector on the basis of the SSRI case
| Autor: | Hernandez, Juan Francisco, van Thiel, Ghislaine J. M. W., Mantel-Teeuwisse, Aukje K., Raaijmakers, Jan A. M., Pieters, Toine, Sub History and Philosophy of Science, Sub Pharmacoepidemiology, Sub Gen. Pharmacoepi and Clinical Pharm, Sub Pharmacotherapy, Theoretical, Pharmacoepidemiology and Clinical Pharmacology |
|---|---|
| Přispěvatelé: | Ethics, Law & Medical humanities, EMGO - Quality of care |
| Rok vydání: | 2014 |
| Předmět: |
Suicide Prevention
CONFIDENCE Drug Industry Compromise media_common.quotation_subject PROFESSION Creating shared value Trust MEDIA PUBLIC TRUST Drug Discovery Health care BENEFITS MANAGEMENT Humans Competence (human resources) media_common Pharmacology RISK business.industry Environmental resource management Public relations ANTIDEPRESSANTS Antidepressive Agents HEALTH-CARE Public trust INSTITUTIONS business Blind trust Selective Serotonin Reuptake Inhibitors |
| Zdroj: | Hernandez, J F, van Thiel, G J M W, Mantel-Teeuwisse, A K, Raaijmakers, J A M & Pieters, T 2014, ' Restoring trust in the pharmaceutical sector on the basis of the SSRI case ', Drug Discovery Today, vol. 19, no. 5, pp. 523-527 . https://doi.org/10.1016/j.drudis.2013.11.019 Drug Discovery Today, 19(5), 523. Elsevier Ltd Drug Discovery Today, 19(5), 523-527. Elsevier Limited |
| ISSN: | 1359-6446 |
| DOI: | 10.1016/j.drudis.2013.11.019 |
| Popis: | The lack of public trust in the pharmaceutical sector (i.e. industry, authorities and doctors) could compromise the future of drug development and the regulatory system. Public trust integrates two important components, namely the vulnerability of the truster and the competence of the trustee. Because trust appears to have eroded as a result of drug safety controversies, this paper analyzes the role of public trust during the selective serotonin reuptake inhibitor (SSRI) and suicidality controversy focusing on the aforementioned trust components. Because the competence component of trust is argued to be paramount in determining and maintaining public trust, the SSRI case shows that this component is a part of public trust where these institutions can build on, and might therefore be better used to substantiate and reinforce, public trust. Efforts to build trust should rely on the ethical, professional (competence) and societal commitment of institutions and individuals to protect the vulnerability of the public during controversies. Because shared values can create trust or increase its levels within a specific environment, industry, authorities and physicians ought to develop novel and cooperative strategies to highlight their shared values and motivations. Rules, regulations and settlements are indispensable tools but undue regulation is costly and can backfire on the rather sensitive trust relationships in the pharmaceutical sector. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect